(Q35015862)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12464154%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

review article

1 reference

title

Cytokine blocking agents in dermatology (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12464154%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

author

Christopher Griffiths

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12464154%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

author name string

J D L Williams

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12464154%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

publication date

1 October 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12464154%20AND%20SRC:MED&resulttype=core&format=json

Clinical and Experimental Dermatology

15 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12464154%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

volume

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12464154%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12464154%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

page(s)

585-590

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12464154%20AND%20SRC:MED&resulttype=core&format=json

Construction and initial characterization of a mouse-human chimeric anti-TNF antibody

15 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2002.01149.X

Successful treatment of severe recalcitrant psoriasis with combination infliximab and methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2002.01149.X

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2002.01149.X

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2002.01149.X

Remission of Behçet's syndrome with tumour necrosis factor alpha blocking therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2002.01149.X

Polymyalgia rheumatica and pericardial tamponade.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2002.01149.X

Successful treatment of SAPHO syndrome with infliximab: report of two cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2002.01149.X

Hidradenitis suppurativa and Crohn's disease: response to treatment with infliximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2002.01149.X

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2002.01149.X

Control of scarring in adult wounds by neutralising antibody to transforming growth factor beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2002.01149.X

Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2002.01149.X

Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2002.01149.X

Treatment of recalcitrant orogenital ulceration of Behçet's syndrome with infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2002.01149.X

Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFalpha antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2002.01149.X

Infliximab (anti-tumor necrosis factor alpha antibody): a novel, highly effective treatment of recalcitrant subcorneal pustular dermatosis (Sneddon-Wilkinson disease)

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2002.01149.X

Antitumour necrosis factor-alpha antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2002.01149.X

Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2002.01149.X

Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2002.01149.X

Treatment of recalcitrant cicatricial pemphigoid with the tumor necrosis factor alpha antagonist etanercept

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2002.01149.X

Common variable immunodeficiency treated with a recombinant human IgG, tumour necrosis factor-alpha receptor fusion protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2002.01149.X

10.1046/J.1365-2230.2002.01149.X

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12464154%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

1 reference